Mr. Collard joined Veloxis in December of 2015 as Chief Executive Officer. He has over 23 years of experience in the pharmaceutical industry.
Mr. Collard is currently a Board member of BioMarck Pharmaceuticals and Hilltop Home Foundation. In 2003, Mr. Collard founded Cornerstone Therapeutics, where he became Chairman and CEO; Cornerstone Therapeutics was later sold to Chiesi Farmaceutici (2014).
Mr. Collard started his career at Dura Pharmaceuticals where he served in numerous sales and marketing roles within the Company. He left Dura in 1998 and joined DJ Pharma, Inc., which was sold to Biovail in 2000.
Mr. Collard holds a B.S. in Engineering from the Southern College of Technology (now Southern Polytechnic State University) in Marietta, Georgia.
Dr. Meier-Kriesche joined Veloxis in September 2017 as Chief Scientific Officer.
Dr. Meier-Kriesche is a board certified Nephrologist with over 20 years of practical clinical experience in transplantation. He is the author of over 170 scientific publications that have appeared in numerous peer-reviewed journals, including the New England Journal of Medicine. Additionally, Dr. Meier-Kriesche served on the faculty of the University of Florida Medical School from 2001 until 2011.
Prior to joining Veloxis, Dr. Meier-Kriesche was the Clinical Trials Lead Immunology at Bristol-Myers Squibb. Dr. Meier-Kriesche has also worked for Astellas Pharma. His industry experience covers Medical Affairs, Drug Development and Outcomes Research in Nephrology, Gastroenterology, Oncology, Lupus and Dermatology.
Dr. Meier-Kriesche earned his medical degree at the University of Perugia in Italy and completed his specialty board in nephrology at the University of Cagliari. He has practiced medicine in the United States, Germany, and Italy.
Mr. Marott joined Veloxis in April 2018 as Chief Financial Officer.
Mr. Marott has been an M&A and healthcare investment banker for 10 years and most recently ran Deutsche Bank's US specialty & generic pharmaceuticals investment banking coverage in New York. Mr. Marott also spent more than 2 years with Citigroup equity research in New York covering the US specialty & generic pharmaceuticals sector.
Prior to his Wall Street career, Mr. Marott was a corporate law and M&A focused attorney for over 7 years with two of Denmark's largest law firms, Hjejle Gersted & Mogensen and Bech-Bruun & Trolle, in Copenhagen.
Mr. Marott holds an MBA with concentrations in both finance and accounting from the Wharton School of the University of Pennsylvania, an executive degree in business administration with a concentration in accounting, HD(R), from Copenhagen Business School, and a Bachelor and Master of Law, cand.jur., from the University of Copenhagen.
Ms. Duarte joined Veloxis in February 2016 as Controller and Vice President of Finance.
Ms. Duarte has over 25 years' experience in a variety of finance and accounting positions, including 10 years in the pharma industry. Prior to joining Veloxis, she served as the Senior Director, Corporate Finance for Chiesi USA. She was the Director of Accounting and Financial Planning at Cornerstone Therapeutics and was a core member of the team guiding the sale of Cornerstone Therapeutics to Chiesi Farmaceutici.
Before transitioning to an in-house role, Ms. Duarte held various roles from Staff to Senior Manager at EY, managing financial statement audits, SEC filings and IPOs for clients.
Ms. Duarte is a Certified Public Accountant and holds a Bachelor of Science in Accounting from Florida Atlantic University.
Mr. Fleshman joined Veloxis in March 2016 as Vice President of Strategy and Corporate Development. Mr. Fleshman has 18 years of commercial experience in business development and marketing within the biopharmaceutical and medical device industries. Prior to joining Veloxis, Mr. Fleshman was Senior Director of Strategy and Business Development at Chiesi USA, Inc. In addition, Mr. Fleshman has held marketing roles at Genzyme Corporation, Cornerstone Therapeutics, Inc. and Ther-Rx Corporation.
Mr. Fleshman holds a Bachelor of Science in Business Administration from Olin Business School at Washington University in St. Louis.
Mr. Hensley joined Veloxis in April 2016 as National Sales Director and was promoted to Vice President, Head of Sales in May 2017. Mr. Hensley has more than 10 years’ experience in a variety of pharmaceutical sales positions, including National Accounts with a focus on GPO and large IDN contracts as well as various senior sales leadership roles at Cornerstone Therapeutics and Chiesi USA.
Mr. Hensley holds a Bachelor of Science in Biology with a minor in Chemistry from the University of North Texas.
Mrs. Wheeler joined Veloxis in March 2016 as Vice President of Operations.
Mrs. Wheeler has more than 18 years' experience managing global pharmaceutical supply chains at Biovail, Cornerstone Therapeutics, and Chiesi USA. At Chiesi USA, she was responsible for a wide variety of products with complex, international supply chains spanning a variety of licensing, purchase and manufacturing arrangements.
Mrs. Wheeler holds a Bachelor of Science from North Carolina State University.
Noel Barnard was named Senior Director, Legal of Veloxis Pharmaceuticals, Inc. in March 2016. Mr. Barnard is responsible for overseeing all aspects of Veloxis's legal affairs around the world.
Previously, Mr. Barnard was assistant general counsel at Chiesi USA, Inc. In that capacity, Mr. Barnard held broad responsibilities that included overseeing of the company's intellectual property portfolio and commercial contracting function. Mr. Barnard also served as assistant general counsel at Cornerstone Therapeutics Inc. prior to its acquisition by Chiesi Farmaceutici S.p.A.
Mr. Barnard, a native of Cookeville, TN, holds a bachelor's degree in biomedical engineering from the University of Tennessee in 2008 and a Juris Doctor from the University of North Carolina School of Law.